Michael Baker

Michael Baker

Company: Arovella Therapeutics

Job title: CEO


Unlocking the Groundbreaking Potential of iNKT Cells for Allogeneic Cancer Therapy 2:00 pm

Arovella is developing its novel iNKT cell therapy platform to develop allogenic cell therapies to treat cancer. Arovella is initially targeting haematological malignancies with its lead product ALA-101. Through a strategic collaboration with Imugene, Arovella will use ALA-101 to target solid tumours. Arovella is also developing its DKK1- CARiNKT cells to target multiple myeloma and…Read more

day: Day Two

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.